Cerebrolysin vs Semax

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.

Semax is believed to upregulate brain-derived neurotrophic factor (BDNF) and other neuroprotective factors, enhancing neuronal survival and synaptic plasticity. It modulates the dopaminergic and serotonergic systems, contributing to its reported effects on mood and focus. Its mechanism of action differs from classical stimulants — it does not act on adrenergic receptors and does not produce typical stimulant tolerance or dependence patterns.

Semax (MEHFPGP) is a synthetic heptapeptide derived from the N-terminal fragment of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension to enhance stability, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and neuroprotective agent, and registered in Russia as a pharmaceutical for cognitive disorders, ischemic stroke, and cerebrovascular insufficiency. Semax modulates BDNF and NGF expression in neural tissue, influences dopaminergic, serotonergic, and cholinergic activity, and is proposed to exert neuroprotective effects in ischemic conditions by reducing neuroinflammation and supporting neuronal survival following cerebrovascular events. Human clinical studies published in peer-reviewed Russian neurology journals (Zh Nevrol Psikhiatr Im S.S. Korsakova) — indexed in PubMed — have examined semax in ischemic stroke patients and cerebrovascular insufficiency, reporting improvements in neurological outcomes and cognitive function; these studies document genuine clinical investigation, though no blinded Western RCTs or external replications exist. Semax is approved in Russia for clinical use in ischemic stroke and cognitive disorders; it has no FDA approval and is not approved in any Western jurisdiction, and while the Russian clinical evidence reflects substantial investigational work, the absence of independently conducted Western trials limits confidence in translating the reported findings to broader clinical recommendations. Semax is available in both standard and N-acetyl semax (N-acetyl-Semax) formulations; N-acetyl semax is considered to have enhanced lipophilicity and potentially extended biological activity, though direct comparative clinical data between formulations is limited. Intranasal administration — semax nasal spray — is the primary delivery route in Russian clinical practice and the form used in the published clinical research, offering rapid mucosal absorption and CNS delivery. Semax nasal spray formulations at 0.1% and 1% concentrations have been used in the Russian clinical program for stroke and cognitive disorder indications; subcutaneous injection is more common in international research compound contexts.